Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares shot up 3.1% during mid-day trading on Tuesday . The stock traded as high as $12.23 and last traded at $12.23, with a volume of 72,944 shares. The stock had previously closed at $11.86.

Several brokerages recently issued reports on SNDX. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 22nd. Morgan Stanley initiated coverage on shares of Syndax Pharmaceuticals in a report on Monday, March 28th. They set an “overweight” rating and a $22.00 price objective on the stock. Oppenheimer Holdings Inc. restated a “buy” rating and set a $24.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 17th. JMP Securities initiated coverage on shares of Syndax Pharmaceuticals in a report on Monday, March 28th. They set an “outperform” rating and a $28.00 price objective on the stock. Finally, Citigroup Inc. initiated coverage on shares of Syndax Pharmaceuticals in a report on Monday, March 28th. They set a “buy” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Syndax Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $25.00.

The firm’s market cap is $215.16 million. The firm has a 50-day moving average of $11.82 and a 200-day moving average of $13.13.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, May 16th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.48) by $2.37. Analysts forecast that Syndax Pharmaceuticals Inc. will post ($2.93) EPS for the current year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.